---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-071413"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:45:27.454706+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M

## Summary
- ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).
- 2025 ARCALYST net revenue guidance raised to $625-640M from prior $590-605M, reflecting continued commercial execution.
- Net income of $17.8M in Q2 2025 vs net loss of $3.9M in Q2 2024; cash and investments $307.8M, no debt.
- KPL-387 Phase 2/3 trial in recurrent pericarditis recruiting; Phase 2 data expected in 2H 2026.
- Approximately 15% of target 14,000 multiple-recurrence pericarditis patients currently on ARCALYST.

## SEC filing metadata
- accession: 0001104659-25-071413
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/0001104659-25-071413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/tm2521890d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-071413
- JSON: https://secwatch.observer/filing/0001104659-25-071413.json
- Plain text: https://secwatch.observer/filing/0001104659-25-071413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.